Drug intelligence / Profile preview

RGB9065

Development stage: Preclinical
Lead developer: Hangzhou Ruipu Chenchuang Technology
Modality: Cell Therapies
Administration: Infusion

Overview

RGB9065 is an allogeneic islet cell therapy being developed by Hangzhou Reprogenix Bioscience for the treatment of diabetes. As a cell replacement therapy, it involves the transplantation of allogeneic islet (beta) cells to restore endogenous insulin production and physiological glucose regulation. Unlike autologous therapies, RGB9065 uses donor-derived cells, which may allow for a more standardized and scalable treatment approach. The program is currently in the preclinical and IND-enabling stage.

Other names: allogeneic islet cell therapy异体胰岛细胞治疗项目

Beyond the preview

Go deeper on RGB9065.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGB9065.

Explore the full profile